1. Home
  2. MRCY vs ACAD Comparison

MRCY vs ACAD Comparison

Compare MRCY & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mercury Systems Inc

MRCY

Mercury Systems Inc

N/A

Current Price

$77.20

Market Cap

5.0B

Sector

N/A

ML Signal

N/A

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

N/A

Current Price

$20.56

Market Cap

4.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MRCY
ACAD
Founded
1981
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
4.4B
IPO Year
1997
2000

Fundamental Metrics

Financial Performance
Metric
MRCY
ACAD
Price
$77.20
$20.56
Analyst Decision
Buy
Buy
Analyst Count
12
20
Target Price
★ $109.00
$30.53
AVG Volume (30 Days)
525.3K
★ 1.6M
Earning Date
11-10-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
23.08
★ 69.12
EPS
N/A
★ 0.20
Revenue
★ $983,622,000.00
$726,437,000.00
Revenue This Year
$10.41
$18.71
Revenue Next Year
$11.49
$12.44
P/E Ratio
★ N/A
$103.10
Revenue Growth
7.85
★ 40.45
52 Week Low
$65.04
$18.39
52 Week High
$128.45
$30.96

Technical Indicators

Market Signals
Indicator
MRCY
ACAD
Relative Strength Index (RSI) 45.33 44.42
Support Level $72.04 $20.10
Resistance Level $87.78 $20.57
Average True Range (ATR) 3.38 0.57
MACD 0.65 0.37
Stochastic Oscillator 49.58 78.37

Price Performance

Historical Comparison
MRCY
ACAD

About MRCY Mercury Systems Inc

Mercury Systems Inc is a commercial technology company serving the aerospace and defense industry. The company envisions, creates, and delivers secure open architecture solutions powering a broad range of mission-critical applications in challenging and demanding environments. Its Mercury Processing Platform spans the full breadth of signal processing from radio frequency front end to the human-machine interface to convert meaningful data, gathered in remote and hostile environments, into critical decisions. The company manufactures components, products, modules, and subsystems and sells to defense prime contractors, the U.S. government, original equipment manufacturers, and commercial aerospace companies. Geographically, it derives maximum revenue from the United States.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: